HYBIO PHARMACEUTICAL CO. LTD.

• Доступно на:
• English
• Русский

Hybio, founded in 1998, is a pioneer in the peptide pharmaceutical industry in China. It became the first company to go public in this field in 2011, with a stock code of 300199. Our company offers a comprehensive range of peptide products, including both active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). In addition, we provide valuable services in contract research and development (CRO) and contract development and manufacturing organization (CDMO) for peptides.

As part of the Hybio Group, we have established eight subsidiaries and branches across different locations. These include our API production base in Wuhan, our FDF production base in Pingshan, our medical device base in Changee, and our hemp processing base in Dali Biotech. These subsidiaries contribute to our overall capabilities and operational excellence.

Hybio's headquarters in Shenzhen has undergone rigorous inspections and obtained certifications from local and national regulatory authorities such as the National Medical Products Administration (NMPA). We have also successfully passed inspections from international regulatory bodies, including the FDA, EU, ANVISA, and KFDA, among others. Additionally, we have undergone numerous customer audits, highlighting our commitment to quality and compliance. Notably, our company holds more than 300 invention patents and 102 Patent Cooperation Treaty (PCT) applications, with over 100 patents being authorized.

Our Wuhan subsidiary serves as a specialized peptide API manufacturing base, which commenced production in 2019. It has a maximum annual capacity of 1000kg for peptide APIs, with the current capacity being approximately 300kg per year. We specialize in the production of various key APIs, including Liraglutide, Semaglutide, Tirzepatide, Glatiramer, Ganirelix, Cetrorelix, Degarelix, Atosiban, Oxytocin, Carbetocin, Terlipressin, Desmopressin, Linaclotide, Plecanatide, Leuprorelin, Triptorelin, Teriparatide, Eptifibatide, Octreotide, Lanreotide, and Somatostatin, among others.

With our extensive expertise, cutting-edge facilities, and commitment to advancing the peptide pharmaceutical industry, Hybio is poised to lead the market and deliver high-quality peptide products and services to our customers.